Company profile for Nasus Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Nasus pharma develops powder-based Intranasal ( PBI ) specialized product portfolio, to address acute medical conditions & Public Health Threats. Based on its unique microsphere technology Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations. Intranasal administration is most suitable for those situations in which rapid drug delivery is required ...
Nasus pharma develops powder-based Intranasal ( PBI ) specialized product portfolio, to address acute medical conditions & Public Health Threats. Based on its unique microsphere technology Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers multiple advantages such as rapid drug delivery, ease of use, non-invasiveness, and safety.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
Yigal Alon 65, Tel Aviv-Jaffa, Israel 6744317
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/20/3191893/0/en/Nasus-Pharma-Strengthens-Leadership-Team-Appointing-Eyal-Rubin-as-Executive-Vice-President-and-Chief-Financial-Officer.html

GLOBENEWSWIRE
20 Nov 2025

https://www.globenewswire.com/news-release/2025/11/18/3189920/0/en/Nasus-Pharma-Announces-Initiation-of-Phase-2-Clinical-Study-of-NS002-with-First-Participant-Dosed.html

GLOBENEWSWIRE
18 Nov 2025

https://www.globenewswire.com/news-release/2025/11/06/3182540/0/en/Nasus-Pharma-Announces-Approval-from-Health-Canada-to-Initiate-Planned-Phase-2-Clinical-Study-of-NS002-Intranasal-Epinephrine-Powder.html

GLOBENEWSWIRE
06 Nov 2025

https://www.globenewswire.com/news-release/2025/10/08/3163304/0/en/Nasus-Pharma-Announces-Expanded-Agreement-to-Support-Development-and-Commercialization-of-NS002-Intranasal-Epinephrine-Program.html

GLOBENEWSWIRE
08 Oct 2025

https://www.globenewswire.com/news-release/2025/09/02/3142595/0/en/Nasus-Pharma-Announces-Upcoming-Presentation-at-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html

GLOBENEWSWIRE
02 Sep 2025

https://www.globenewswire.com/news-release/2025/08/26/3139216/0/en/Nasus-Pharma-Marks-NYSE-American-Listing-with-Bell-Ringing-Ceremony.html

GLOBENEWSWIRE
26 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty